Clinical Trials
5 trialsNCT00002663 2023-02-13
Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies
Atara Biotherapeutics
Phase 1/2 Completed
NCT01748721 2016-01-08
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Morphotek
Phase 1 Completed
NCT00099255 2014-12-18
Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma
Seagen Inc.
Phase 2 Completed
NCT00051597 2011-10-12
A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies
Seagen Inc.
Phase 1/2 Completed
NCT00298467 2010-04-26
MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma
Bristol-Myers Squibb
Phase 2 Withdrawn